We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Positivitea is a range of teas based on the chakras. They are already stocked in over 80 locations throughout the UK and Europe including Urban Outfitters and Fenwick. The use of the proceeds raised will go towards expanding the team and getting Positivitea in more retail outlets and being used by more suppliers.
days to go: Expired investment: £103,640
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £134,892
The Five Points Brewing Company (TFPBC) is one of London's best-known craft breweries that brews modern, flavourful, craft beer, The company asserts that its beers are stocked nationwide in pubs and across major chains like Waitrose, Tesco and Nando's. TFPBC claims that it has grown from £173,000 worth of sales in 2013 to £4.8 million in 2019. The company's first pub, The Pembury Tavern, has been graced with awards and recommendations from multiple entities. TFPBC argues that it has developed its e-commerce site in the wake of COVID-19 achieving online sales of over £300,000 from selling three million pints in draught, bottle and can form since March 2020. It also won the Champion Beer Of London 2019 Award. The company will use the investment to open its new on-site taproom with a large outdoor area for beer sales direct to the public, build a new flagship brewery site in Hackney, drive new sources of revenue whilst reducing costs, and maintain its commitment to East London
days to go: Expired investment: £841,392
Peckwater Brands (PB) is a company engaged in the growing cloud kitchen/delivery business that runs virtual restaurant brands from the kitchens of existing restaurants. It argues that restaurants need to pay high street rents and staff wages no matter how many diners visit. Nearly 5,000 restaurants have closed in the UK since 2015 due to not being able to fulfil these tasks. PB aims to change this scenario. It helps restaurant partners use their existing staff and kitchen capacity better, and help keep struggling businesses running. The company received more than 10,000 customer orders through Deliveroo and Uber Eats. It witnessed more than £250,000 in customer sales since June 2020 and is spread across London, Manchester, Leeds, and Coventry. PB has launched four brands with four more in the pipeline. It will use the investment to get more partners, launch more brands, and acquire more customers.

Pitch Rated

69%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £232,208
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph